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Inflammatory markers and adrenocorticotropic hormone (ACTH) stimula-
tion test results may help us recognise critically ill dogs with poor disease out-
come. Systemic inflammatory response syndrome (SIRS) criteria, the fast version 
of the Acute Patient Physiologic and Laboratory Evaluation Score (APPLEfast), 
complete blood count, albumin and C-reactive protein (CRP) levels, baseline and 
stimulated cortisol levels and Δcortisol value were recorded in 50 client-owned 
dogs admitted to the Small Animal Hospital of the University of Veterinary Med-
icine Budapest with various inflammatory or neoplastic conditions. Increasing 
APPLEfast score was associated with a decreasing chance of survival (P = 0.0420). 
The Δcortisol value was significantly higher in SIRS dogs than in non-SIRS dogs 
(mean ± SD ΔcortisolSIRS: 342.5 ± 273.96; mean ± SD Δcortisolnon-SIRS: 175.3 ± 
150.35; P = 0.0443). Elevated baseline or stimulated cortisol levels were associat-
ed with a higher chance of non-survival (P = 0.0135 and P = 0.0311, respective-
ly). These data indicate that pathologically higher baseline and stimulated cortisol 
levels represent an exaggerated stress response in critically ill dogs, which is neg-
atively associated with survival.  
Key words: SIRS, ACTH stimulation test, adrenal dysfunction, outcome, 
dog  
Critical illness-related corticosteroid insufficiency (CIRCI) is a well-known 
entity in human medicine (Beishuizen and Thijs, 2001; Venkatesh and Cohen, 
2011) and has been described in dogs (Goy-Thollot et al., 2006; Burkitt et al., 
2007; Martin et al., 2008; Burkitt Creedon, 2015) as well. During critical illness, 
circulating cortisol contributes to maintaining vascular tone and integrity, aug-
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ments the effect of catecholamines, and plays a crucial role in the resolution of 
inflammation. Inadequate activation of the hypothalamic–pituitary–adrenal (HPA) 
axis leads to relative hypocortisolaemia and/or target cell glucocorticoid defi-
ciency. CIRCI is a condition distinct from Addison’s disease, accompanied by 
transient adrenocortical dysfunction (Galac et al., 2009; Prittie, 2009; Martin, 2011). 
Beyond several hormonal and neurogenic signals, pro-inflammatory cyto-
kines are known to activate the HPA axis. However, they are also able to inhibit 
the function of the HPA axis, interfering with corticotropin-releasing hormone 
(CRH), adrenocorticotropic hormone (ACTH) and cortisol release. The peripher-
al metabolism of cortisol at target tissue level could also be deranged (Galac et 
al., 2009; Prittie, 2009; Martin, 2011; Burkitt Creedon, 2015). 
Early identification of patients with CIRCI should be a priority in clinical 
practice. The ACTH stimulation test (ACTHST) with a standard dose of synthetic 
ACTH (5 μg/kg tetracosactide) is used to diagnose hypoadrenocorticism in dogs 
(Kemppainen et al., 2005). However, this supraphysiologic dose is not sensitive 
enough to detect slight alterations during CIRCI (Beishuizen and Thijs, 2001; 
Martin et al., 2007; Prittie, 2009; Behrend et al., 2013). It is more accurate to as-
sess adrenocortical reserve capacity in critically ill dogs with 0.5 μg/kg tetraco-
sactide (Martin et al., 2007; Martin, 2011). 
Serum C-reactive protein (CRP) is the main positive acute-phase protein in 
dogs, produced almost exclusively by hepatocytes in response to circulating pro-
inflammatory mediators (Gebhardt et al., 2009). The elevation of CRP reflects 
the severity and extension of systemic inflammation irrespective of the underly-
ing mechanism (infection, immune-mediated disease, trauma, neoplasia, etc.), and 
thus CRP is used as a biomarker of systemic inflammatory response syndrome 
(SIRS) (de Laforcade, 2009; Gebhardt et al., 2009; Whittemore et al., 2011). 
A clinical scoring system including SIRS diagnostic criteria and the fast 
version of the Acute Patient Physiologic and Laboratory Evaluation Score  
(APPLEfast score) is widely used in small animal medicine, as it enables a quick 
and objective identification of critically ill patients (de Laforcade, 2009; 
Gebhardt et al., 2009; Hayes et al., 2010). 
The main goal of this study was to assess the relationship between in-
flammatory markers used in the clinical setting and ACTHST results in critically 
ill dogs. In addition, we also investigated the relationship of cortisol levels and 
Δcortisol value with survival. 
 
Materials and methods 
Study population 
Fifty client-owned dogs with suspected SIRS admitted to the Small Ani-
mal Hospital of the University of Veterinary Medicine Budapest (UVMB) be-
tween January 2014 and August 2016 were included in the study, with various 
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inflammatory or neoplastic conditions. Patients having pre-existing adrenal dis-
ease or receiving medications affecting the HPA axis (e.g. glucocorticoids, pro-
gestin, major analgesics, azole antifungals) were excluded. All dogs underwent a 
complete physical examination, and blood was obtained within 24 h after hospi-
tal admission. Patients were considered having SIRS when they fulfilled at least 
two out of four criteria (Table 1) (de Laforcade, 2009). The APPLEfast score (cal-
culated from albumin, glucose and lactate level, mentation score, and platelet 
count) was recorded in all dogs (Hayes et al., 2010). ACTHST was performed by 
administering 0.5 µg/kg of a synthetic ACTH compound (Synachten 250 µg/ml inj., 
Novartis) intravenously. Serum cortisol level was measured prior to and 60 min 
after ACTH administration. The Δcortisol value was calculated [Δcortisol = 
(stimulated cortisol) – (baseline cortisol)]. The final diagnoses were established 
based on medical history, clinical signs, routine laboratory and diagnostic imag-
ing, cytology/histopathology findings and/or the pathology report. Dogs classified 
as survivors were alive when discharged from the Intensive Care Unit. Dogs were 
classified as non-survivors if they died or were euthanised during the hospitalisa-
tion period. Patients euthanised due to financial considerations were excluded. 
The owners of all enrolled dogs gave their written consent to the hospitalisation 
and treatment of their dogs. 
Table 1 
Criteria for the diagnosis of systemic inflammatory response syndrome (SIRS) in dogs (de Lafor-
cade, 2009) 
Criterion Value 
Body temperature  < 38.1 °C or > 39.2 °C 
Heart rate > 120/min 
Respiratory rate > 20/min 
White blood cell count, band neutrophil ratio < 6.0 G/l or > 16.0 G/l, > 3% 
 
Sample collection, handling and analysis 
Venous blood was obtained and samples for haematology and clinical 
chemistry were immediately analysed or stored overnight at 4 °C. Serum samples 
for CRP and cortisol assay were stored at –20 °C until assayed. Complete blood 
count was done with Abacus Junior Vet 5 Analyzer (Diatron) and each blood 
film was evaluated microscopically. The biochemistry panel was performed us-
ing an Olympus AU400 Chemistry Analyser. Serum C-reactive protein levels 
were determined from 33 patients by an immunoturbidimetric method previously 
validated for canine samples (Canine CRP Diasystem Scandinavia) according to 
the manufacturer’s instruction. Serum cortisol concentrations were determined 
using a chemiluminescent immunoassay (Immulite1000, Siemens) validated for 
use with canine serum samples. Concentrations above the detection range (corti-
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sol > 1380 nmol/l; CRP > 220 mg/l) were reported as cortisol 1380 nmol/l and 
CRP 220 mg/l. None of the samples were extremely haemolytic or lipaemic. 
Statistical analysis 
Statistical analysis was done by the statistical program R 3.2.3 (R Core 
Team, 2015). Variables of interest were baseline and stimulated cortisol level, 
Δcortisol value, body temperature, SIRS criteria, APPLEfast score, total white 
blood cell (WBC) count, absolute number of band neutrophils and lymphocytes, 
albumin level and C-reactive protein concentration. 
For the continuous variables (Δcortisol value, body temperature, APPLEfast 
score, total WBC count, absolute number of band neutrophils and lymphocytes, al-
bumin level and C-reactive protein concentration) mean ± SD and ranges are re-
ported, and group comparisons were made by Student’s t-test and Spearman’s rank 
correlation. For the comparison of categorical variables (SIRS criteria, survival cri-
teria, baseline and stimulated cortisol level) Fisher’s exact test was done. A logistic 
regression model was used to assess the strength of the relationship between AP-
PLEfast score and disease outcome. ACTHST was performed in all dogs, but the 
stimulated cortisol level of two dogs was not measured due to insufficient sample 
volume, and four patients with cortisol levels t0 and/or t1h > 1380 nmol/l were ex-
cluded from the statistical analysis. The cut-off value of Δcortisol was calculated 
from data of 44 dogs to predict the chance of survival. For the statistical analyses 
dogs were pooled in the following groups: baseline cortisol levels within the refer-
ence interval (40–110 nmol/l) or elevated (≥ 110 nmol/l), stimulated cortisol levels 
within (150–470 nmol/l), above (> 470 nmol/l) or below (< 150 nmol/l) the refer-
ence range. A value of P < 0.05 was considered significant for all tests. 
 
 
Results 
The 50 dogs meeting the inclusion criteria included 26 males (12 castrated) 
and 24 females (13 spayed). The breeds represented included 7 mixed-breed dogs, 
4 German Shepherds, 3 Yorkshire Terriers and Golden Retrievers each, 2 Bichon 
Bolognese, Bichon Havanese, English Cocker Spaniels, Dachshund, Dobermans, 
Pugs, West Highland White Terriers each, and one dog each of 19 other breeds. 
The median age was 7 years (range: 5 months to 15.5 years). The mean age of non-
survivors (8.7 ± 3.8 years, range: 0.9–15.5 years) was significantly higher than that 
of the survivors (6.4 ± 3.7 years, range: 0.4–13.5 years, P = 0.0461). The median 
body weight was 22.5 kg (range: 2–65 kg). Forty-one dogs (82%) were diagnosed 
with inflammatory disease: peritonitis (n = 8), inflammatory bowel disease (n = 5), 
acute haemorrhagic diarrhoea syndrome (n = 3), septicaemia (n = 3), fever of un-
known origin (n = 2), diabetes mellitus and pancreatitis (n = 2), pleuropneumonia 
(n = 2), bronchopneumonia (n = 2), aspiration pneumonia (n = 2), septic pleuritis 
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(n = 2), bite wounds (n = 2), immune-mediated haemolytic anaemia (n = 2), gas-
troenteritis (n = 1), endocarditis (n = 1), mastitis (n = 1), abscess (n = 1), babesiosis 
(n = 1), immune-mediated polyarthritis (n = 1). Nine dogs (18%) had neoplastic 
disorders: mammary gland carcinoma (n = 2), small-cell lung carcinoma (n = 1), 
high-grade multicentric lymphoma (n = 1), alimentary B-cell lymphoma (n = 1), 
high-grade squamous cell carcinoma (n = 1), metastatic haemangiosarcoma (n = 
1), pulmonary metastasis (n = 1), and abdominal sarcoma (n = 1). 
The majority of the dogs (32/50; 64%) were discharged from the hospital, 
but 18/50 patients (36%) died or were euthanised during the hospitalisation period. 
Overall, 32/50 dogs (64%) fulfilled the diagnostic criteria for SIRS: 5/9 
patients (56%) with neoplasia and 27/41 dogs (66%) with inflammatory disease. 
Disease outcome did not differ in the SIRS and non-SIRS groups. There was no 
correlation between SIRS and baseline or stimulated cortisol concentration, but 
the Δcortisol value was significantly different in the SIRS and non-SIRS groups 
(mean ΔcortisolSIRS: 342.5 ± 273.96 nmol/l and mean Δcortisolnon-SIRS: 175.3 ± 
150.35 nmol/l, P = 0.0148) (Fig. 1). 
 
Fig. 1. Δcortisol value of the SIRS and the non-SIRS group (mean ΔcortisolSIRS: 342.5 ± 
273.96 nmol/l, mean Δcortisolnon-SIRS: 175.3 ± 150.35 nmol/l; P = 0.0148) 
 
There was no significant correlation between APPLEfast score and cortisol 
t0, t1h levels or Δcortisol value. However, there was a significant relationship be-
tween increasing APPLEfast score and decreasing chance of survival [mean for 
survivors: 24.09 ± 3.62, mean for non-survivors 26.89 ± 5.29, OR = 0.86, CI 95%: 
(0.79; 0.92), P = 0.042] (Fig. 2). 
The rectal temperature was recorded at the time of blood sampling. Thirty-
one patients (62%) had normal body temperature (38.0–39.2 °C), 8 dogs (16%) 
had fever, and 11 dogs (22%) were suffering from hypothermia. Higher body 
temperature was statistically correlated with elevated serum CRP concentration 
(Spearman’s rank correlation, P = 0.0255, ρ = 0.39). 
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Fig. 2. APPLEfast score in survivor and non-survivor dogs [meansurvivor: 24.09 ± 3.62,  
meannon-survivor: 26.89 ± 5.29; OR = 0.86, CI 95%: (0.79; 0.92), P = 0.042] 
 
Serum C-reactive protein was measured in 33 patients, all of which had 
elevated values (mediancrp: 101.6 mg/dl, meancrp: 130.6 ± 87.20 mg/dl, range: 
18.9–406.1 mg/dl). Although the mean CRP concentrations of non-survivors 
were higher than those of survivors, the difference was not significant (Table 2). 
Similarly, the mean CRP level showed no significant difference between the 
SIRS group (146.4 ± 94.5 mg/dl) and the non-SIRS group (109.1 ± 74.0 mg/dl). 
CRP was not significantly correlated with cortisol t0 or t1h concentrations. 
The WBC, band neutrophil and lymphocyte counts and albumin concen-
tration were not correlated significantly with the outcome. In addition, there was 
no difference in albumin level between survivor and non-survivor individuals 
(Table 2). 
Elevated baseline cortisol level was associated with an almost ten times 
higher chance of non-survival compared to dogs with baseline cortisol within the 
reference range (OR = 9.71, P = 0.0135) (Fig. 3). 
Patients with stimulated cortisol levels above the reference range had an 
almost four times higher chance of non-survival compared to dogs with corti-
solt1h within or below the reference interval (OR = 3.69, P = 0.0311) (Fig. 4). 
Four patients had baseline and/or stimulated cortisol levels higher than 
1380 nmol/l. Three of them were non-survivors (pancreatitis with peritonitis, 
mammary tumour, peritonitis due to foreign body ileus), and only one dog (with 
babesiosis and implant-related infection in the tibia) was discharged from the 
hospital. 
The Δcortisol value was not significantly different in survivor and non-
survivor patients (Table 2). However, the Δcortisol value was significantly higher 
in SIRS dogs than in non-SIRS dogs (mean ΔcortisolSIRS: 342.5 ± 273.96; mean 
Δcortisolnon-SIRS: 175.3 ± 150.35; P = 0.0443). There was no Δcortisol cut-off val-
ue of acceptable sensitivity and specificity suitable for clinical decision-making. 
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Fig. 3. Baseline cortisol level in survivor and non-survivor dogs (OR = 9.71, P = 0.0135) 
 
 
Fig. 4. Stimulated cortisol level in survivor and non-survivor dogs (OR = 3.69, P = 0.0311) 
 
 
Discussion 
The main purpose of our study was to assess adrenocortical reserve capac-
ity in critically ill dogs and evaluate the possible relationship between the severi-
ty of inflammation and adrenal responsiveness. 
In conformity with the results reported by Giunti et al. (2015), the mortali-
ty rate found in the present study was high and the use of the APPLEfast score 
was helpful in predicting poor disease outcome at the time of hospital admission. 
Our data indicate that a single serum CRP determined at the time of hospi-
tal admission has limited diagnostic value as a marker of survival. Similar find-
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ings were reported by Whittemore et al. (2011) and Giunti et al. (2015). In an-
other study of 61 dogs with septic or non-septic SIRS, the initial serum CRP 
concentration was not associated with disease outcome, but the changes observed 
in a 3-day period had a predictive value regarding survival (Gebhardt et al., 2009). 
Changes in CRP levels in response to therapy could have been more accurate in 
predicting survival in our study population as well. Not surprisingly, body tem-
perature was correlated with C-reactive protein level, as both are consequences 
of the acute-phase response generated by pro-inflammatory mediators. 
Although in our study there was no relationship between CRP and ACTHST 
cortisol concentrations, we find it useful to report even this negative finding, as 
to the best of our knowledge this correlation had not been studied previously. 
We found that the Δcortisol value was significantly higher in the SIRS 
than in the non-SIRS group. This is a correlation that has never been reported be-
fore as far as we know. However, this finding is slightly controversial. On the 
one hand, patients not suffering from SIRS are not sick enough to have an exag-
gerated adrenal response, but on the other hand some dogs with SIRS are ex-
pected to have a blunted cortisol response to ACTH. A possible explanation could 
be that corticosteroid insufficiency is manifested at the receptor level in target 
cells in patients with SIRS, and even an exaggerated cortisol response to ACTH 
is not sufficient to meet the cellular demand (Beishuizen and Thijs, 2001; Ven-
katesh and Cohen, 2011; Burkitt Creedon, 2015). Cellular glucocorticoid deficien-
cy should be investigated in these cases. 
Regarding C-reactive protein level, there was no statistically significant 
difference between the SIRS group and the non-SIRS group. A possible explana-
tion could be that the patients were misclassified regarding their SIRS status: ac-
cording to de Laforcade (2009), diagnostic criteria for SIRS in dogs have a speci-
ficity of only 64% and a sensitivity of 97%. 
Like in previous studies, none of our patients had absolute baseline hypo-
cortisolaemia or abnormal Na+/K+ ratio according to the reference interval estab-
lished for healthy dogs (Prittie et al., 2002; Goy-Thollot et al., 2006; Martin et 
al., 2008). Nevertheless, there is no widely accepted reference range for plasma 
cortisol level in critically ill dogs (Prittie, 2009; Martin, 2011). Sweeney et al. 
(2010) investigated cortisol levels in response to ACTHST in healthy dogs that 
underwent different intensive care procedures (sedation, tracheostomy, intuba-
tion and mechanical ventilation, etc.), but these dogs were not sick, so the effect 
of inflammation on the HPA axis could not be extrapolated.  
Our findings are consistent with the results of previous studies in demon-
strating a positive association between elevated baseline or post-ACTH cortisol 
level and a decreased chance of survival (Goy-Thollot et al., 2006; Schoeman et 
al., 2007; Schoeman and Herrtage, 2008). 
Blunted response to the ACTH stimulation test is identified as an inde-
pendent predictor of poor prognosis in human septic patients (Juutilainen et al., 
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2011). Moreover, the relationship between inappropriate adrenocortical reserve 
capacity and increased risk of death in dogs has been reported: Burkitt et al. 
(2007) found that a Δcortisol value of < 83 nmol/l was associated with increased 
risk of hypotension and poor prognosis in septic dogs. However, the intramuscu-
larly administered synthetic ACTH injection (250 μg/patient) might not be 
properly absorbed in a hypotensive patient. In another study, dogs with sepsis, 
trauma or gastric dilatation and overload were investigated: patients having a 
Δcortisol value of ≤ 83 nmol/l (after 5 μg/kg ACTH iv.) were 5.7 times more likely 
to be treated with vasopressors compared to dogs with Δcortisol > 83 nmol/l, but 
the difference regarding disease outcome was not significant (Martin et al., 2008). 
Schoeman and Herrtage (2008) examined adrenal responsiveness to 5 µg/kg 
ACTH in dogs with Babesia rossi infection. Non-survivor dogs tended to have 
lower Δcortisol values compared to survivors, but the difference was not statisti-
cally significant. In contrast, Goy-Thollot et al. (2006) found that Δcortisol val-
ues were higher in non-survivors than in survivors after intravenous injection of 
250 µg ACTH to critically ill dogs. 
In our study we did not find statistically significant differences in Δcorti-
sol value between survivor and non-survivor dogs. Nevertheless, 17 of the 18 
non-survivor individuals had elevated baseline and/or stimulated cortisol level. 
These dogs might have suffered from CIRCI at the receptor level (target cell hy-
pocortisolism), because they died in face of their hypercortisolaemia. Detailed 
investigation of changes in glucocorticoid receptor profiles of target cells is also 
recommended and may be helpful in understanding the pathomechanism of 
CIRCI. 
The influence of the patients’ age on disease outcome should be consid-
ered in critically ill dogs, as in the present study survivors were significantly 
younger than non-survivors. 
The inclusion of patients with neoplasia might distort the statistical calcu-
lations regarding disease outcome, but SIRS and CIRCI can also develop due to 
an underlying neoplastic condition (Boozer et al., 2005; Bruno et al., 2012). 
As with any clinical study, there are several limitations that should be con-
sidered. The study population was heterogeneous in terms of their illness; how-
ever, SIRS could develop irrespective of the underlying condition (de Laforcade, 
2009). The accurate onset of critical illness in the patients studied was also un-
known. Furthermore, patients prior to hospitalisation could have been already 
treated with intravenous fluids, antibiotics, NSAIDs, etc., which could influence 
the test results and the disease outcome. However, patients receiving medications 
that could directly alter the HPA axis (i.e. glucocorticoids) were excluded from 
the study. 
The small size of study population could also limit the extension of our re-
sults. In addition, our findings might be relevant in the Small Animal Hospital of 
the UVMB and might not be applicable to other institutes. 
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Measurement of the free fraction of cortisol rather than total cortisol level 
has been suggested in critically ill patients, especially in those with hypoalbumi-
naemia (Goy-Thollot et al., 2006; Martin, 2011; Venkatesh and Cohen, 2011). 
Like albumin level, the serum concentration of cortisol-binding globulin (CBG), 
which is the main carrier molecule of circulating cortisol, wanes during inflam-
mation. Decrease in CBG level leads to an elevated unbound, free cortisol con-
centration. The measurement of total cortisol level might underestimate the cir-
culating free cortisol level. Although the determination of free cortisol level 
would have been more accurate for evaluating the degree of hypercortisolaemia 
in our patients, unfortunately it was not available to us. However, it probably 
would not change our conclusions, as there was no difference in albumin level 
between survivor and non-survivor individuals. 
Further studies are necessary to clarify the relationship between systemic 
inflammation and adrenocortical reserve capacity. Serial measurement of plasma 
pro-inflammatory cytokines and/or acute-phase proteins could provide a more 
accurate follow-up of ongoing inflammatory process, and repeated ACTHST 
would be more ideal for assessing adrenocortical reserve capacity during critical 
illness. 
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